Ariston focuses on rapidly bringing clinically proven candidates to market. The current pipeline of 3 compounds for 4 indications includes AST-726 for migraine prevention and for treating vitamin deficiency, AST-914 for a movement disorder, and AST-117 for anxiety. Ariston's business model and extensive internal expertise allows for rapid deployment of resources for efficient clinical development and commercialization.
Headquartered in the greater Boston area, Ariston was founded in 2003 by Paramount Biosciences, LLC, a venture capital group with a substantial track record in the origination and successful development of public and private biopharmaceutical companies.
The current pipeline was acquired by in-licensing (AST-726 in 2003) and by a merger with Pyrenees Pharmaceuticals, Inc. (AST-914 and AST-117 in 2006)
Ariston seeks to in-license additional clinical candidates in the Neurology space. Ariston will seek out-licensing partners for development and commercialization outside the US and for co-commercialization within the US.